Cancer

Recent wins worth $4B to Lilly market value

September 15, 2014
J.K. Wall
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
More

Lilly cancer drug fares well in late-stage study

September 12, 2014
Associated Press
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
More

Costly drugs force cancer docs to weigh price with therapy

May 30, 2014
Bloomberg News
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More

Endocyte stock doubles after key approval in Europe

March 21, 2014
Bloomberg News, J.K. Wall
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
More

Indiana one of many states aiming to limit tanning

March 2, 2014
Associated Press
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
More

Three groups puzzled by woman's $7 million bequest

January 8, 2014
Associated Press
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Small charity eases struggles of breast cancer patientsRestricted Content

October 6, 2012
Dan Human
With volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients. Recipients have ranged in age from 18 to 90.
More

Sledge's exit will keep IU program mostly intact

October 1, 2012
J.K. Wall
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
More

Lilly wins appeal upholding patent for Alimta cancer drug

August 24, 2012
Bloomberg News
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
More

Indiana Blood Center tapping new vein of revenueRestricted Content

July 28, 2012
Mason King
Group sees role in cellular therapy as growth area with profit margins higher than core business.
More

Lilly cancer treatment fails trial in stomach cancer

July 5, 2012
 IBJ Staff and Bloomberg News
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
More

Cancer tools help Roche with Alzheimer's drug

May 13, 2012
Bloomberg News
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
More

WellPoint enrolls IBM supercomputer at IU medical schoolRestricted Content

April 21, 2012
J.K. Wall
IBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying to teach it how to treat cancer.
More

Komen grant recipients cope with controversy they didn't createRestricted Content

April 7, 2012
Kathleen McLaughlin
Local health care providers won’t find an easy replacement for the grant money supplied by Susan G. Komen for the Cure. That money could be in jeopardy, as grass-roots Komen supporters appear to be sitting out of this year’s Race for the Cure in response to a national controversy over grants to Planned Parenthood.
More

Endocyte pulls trigger on European drug submission

March 13, 2012
J.K. Wall
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
More

Endocyte stays course despite being battered by investorsRestricted Content

December 31, 2011
J.K. Wall
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
More

NFP of NOTE: Little Red Door Cancer AgencyRestricted Content

December 31, 2011
 IBJ Staff
Little Red Door Cancer Agency strives to make the most of life and the least of cancer.
More

Q&A

December 27, 2011
J.K. Wall

Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.

More

Q&A

December 5, 2011
J.K. Wall
Carmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
More

Lilly's Alimta get favorable opinion for new use in Europe

September 26, 2011
J.K. Wall
If approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
More

Debate rages over whether Lilly's Byetta lifts cancer risk

September 16, 2011
Bloomberg News
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
More

IU Cancer Center recruits top researcher

September 15, 2011
Scott Olson
Dr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
More
Page  1 2 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Great article and post scripts by Mike L (Great addition to IBJ BTW). Bobby's stubborn as a mule, and doubt if he ever comes back to IU. But the love he would receive would be enormous. Hope he shows some time, but not counting on it.

  2. When the Indiana GOP was going around the State selling the Voucher bill they were promising people that the vouchers would only be for public charter schools. They lied. As usual.

  3. I am Mr. Morris Ray, a Legitimate And a Reputable money Lender. We lend funds out to individuals in need of financial assistance, we give loan to people that have a bad credit or in need of money to pay bills, to invest on business. Have you been looking for loan? you have not to worry, because you are in the right place i offer loan at low interest rate of 2% so if you are in need of a loan i want you to just contact me via this email Address: morris_ray123@outlook.com

  4. Jim, your "misleading" numbers comment is spot on. This is the spin these posers are putting on it. News flash, fans: these guys lie. They are not publicly traded so no one holds them accountable for anything they say. The TV numbers are so miniscule to begin with any "increase" produces double digit "growth" numbers. It's ridiculous to think that anything these guys have done has awakened the marketplace. What have they done? Consolidate the season so they run more races on consecutive weekends? And this creates "momentum." Is that the same momentum you enjoy when you don't race between August and March? Keep in mind that you are running teams who barely make ends meet ragged over the summer to accomplish this brilliant strategy of avoiding the NFL while you run your season finale at midnight on the East Coast. But I should not obfuscate my own point: any "ratings increase" is exactly what Jim points to - the increased availability of NBC Sports in households. Look fans, I love the sport to but these posers are running it off a cliff. Miles wants to declare victory and then run for Mayor. I could go on and on but bottom line for God's sake don't believe a word they say. Note to Anthony - try doing just a little research instead of reporting what these pretenders say and then offering an "opinion" no more informed than the average fan.

  5. If he's finally planning to do the right thing and resign, why not do it before the election? Waiting until after means what - s special election at tax payer expense? Appointment (by whom?) thus robbing the voters of their chance to choose? Does he accrue some additional financial advantage to waiting, like extra pension payments? What's in it for him? That's the question that needs to be asked.

ADVERTISEMENT